Site Management/Investigator Payments Featured Articles

1. Assigned Slot Allocation Offers A Fair Solution For Oncology Phase 1 Trials (Part 2) 4/10/2026

   In part two of this series on slot allocation, Nehal Lakhani, MD, Ph.D. proposes assigned slot allocation as an alternative to competitive placement and discusses how the approach might benefit patients and sites.

2. Slot Allocation Is A Problem For Patients And PIs In Phase 1 Oncology Trials (Part 1) 4/10/2026

   Given the shift in the size and scope of oncology Phase 1 trials, cohort management and slot allocation strategies must change, too. Nehal Lakhani, MD, Ph.D. explains why competitive slot allocation is no longer optimal for patients or PIs.

3. Considerations For Allergic Rhinitis Trials Are Nothing To Sneeze At 4/8/2026

   Inimmune CEO David Burkhart explains how a GSK layoff led to the formation of a new company focused on treating allergic rhinitis. Here, he shares success from the company's approach to site selection, trial design, and timing.

4. Could Study Rehearsals Create A New Standard For Site Readiness? 4/1/2026

   Giving sites the chance to rehearse a trial ahead of their initial study visits could lead to improved readiness, protocol adherence, and participant experience.

5. Research Center Layout Helps Lower Barriers To Cross-Industry Collaboration 3/27/2026

   Discover how one research center, uniquely built for collaboration, enables the collection and analysis of high-quality specimens and data that will fuel both current and future research collaborations.

6. Site Staffing On The Upswing, But Still A Challenge 3/26/2026

   In this final article of the series, Jimmy Bechtel and Ken Getz discuss how workforce pressures have shaped site performance and what’s being done to strengthen site staff retention and career growth.

7. Old Habits, Communication Issues Still Stalling Site Budget Negotiations 3/19/2026

   Drawing from the 2025 SCRS Landscape Survey Report, Jimmy Bechtel and Ken Getz unpack how growing trial complexity, inconsistent fair market value benchmarks, and structural disconnects are reshaping site-sponsor relationships.

8. The Art Of Finding And Keeping The Right KOL 3/18/2026

   Learn from Incyclix CEO Patrick Roberts how the company identifies its KOLs, tailors engagement to their expertise, measures collaboration success, and sustains successful long-term partnerships.

9. Do We Still Need To "Save" Our Sites? 3/11/2026

   Budget negotiations, sponsor expectations, operational pressures, and burnout all remained front-and-center concerns at this year's Save Our Sites (SOS) conference. In this recap, I share key takeaways from the sessions I attended — including practical budgeting advice, sponsor “turn-offs,” and a few unbelievable (but true) sponsor horror stories — along with why gatherings like SOS still matter for the site community.

10. Avoid Clinical Alignment Breakdowns With "Lateral Agility" 3/6/2026

    Internal misalignment can stall the clinical timeline, erode the window of patent protection, and jeopardize funding. Learn why leadership can no longer be and instead must exhibit "lateral agility" across the enterprise.